Management and major shareholders loading up on market recently means that something is brewing behind the scenes and company is undervalued for that reason
Takeover I don’t think will happen unless it’s a massive number because management have made it clear they want to license out each indication. Cardiovascular indication has a 12 billion dollar market potential with the drug having no competition in this space as there is nothing out there to treat heart muscle death after a heart attack. A 4-5 billion dollar license agreement based off deals happening in biotech space on these market size potential with a 600 million dollar upfront payment. On that $10-$12 dollars a stock
Add to My Watchlist
What is My Watchlist?
